Patrick Lamy Sells 875 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 875 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $54.59, for a total value of $47,766.25. Following the completion of the transaction, the vice president now directly owns 31,698 shares in the company, valued at $1,730,393.82. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Patrick Lamy also recently made the following trade(s):

• On Monday, June 16th, Patrick Lamy sold 2,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.14, for a total transaction of $108,280.00.
• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.31, for a total value of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.00, for a total transaction of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total transaction of $339,920.00.

Akero Therapeutics Stock Down 0.3%

Shares of Akero Therapeutics stock traded down $0.17 during trading on Monday, reaching $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of -27.71 and a beta of -0.16. The stock has a fifty day moving average price of $45.88 and a two-hundred day moving average price of $41.25. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. boosted its position in shares of Akero Therapeutics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company's stock valued at $72,000 after acquiring an additional 321 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Akero Therapeutics by 14.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company's stock worth $114,000 after purchasing an additional 338 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after purchasing an additional 390 shares during the period. Amalgamated Bank boosted its holdings in Akero Therapeutics by 19.0% in the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company's stock valued at $104,000 after purchasing an additional 410 shares during the period. Finally, Summit Investment Advisors Inc. grew its position in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after purchasing an additional 450 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on AKRO. HC Wainwright lifted their target price on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Bank of America raised their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, Citigroup cut their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $82.50.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.